Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 7/20 | 0.42 |
| ▸ | F7 | P08709 | 14/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 6/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 6/20 | 0.37 |
| ▸ | F3 | P13726 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 5/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7149887 | 0.92 | F10 (0.43) | F10F7PRSS1PRSS2PRSS3 | |
| SCHEMBL5882284 | 0.89 | F10 (0.52) | F10F7PRSS1PRSS2PRSS3 | |
| SCHEMBL7147021 | 0.87 | F10 (0.41) | F10F7PRSS1PRSS2PRSS3 | |
| SCHEMBL7149864 | 0.82 | F10 (0.49) | F10F7PRSS1PRSS2PRSS3 | |
| SCHEMBL6876129 | 0.82 | F10 (0.39) | F10F7PRSS1PRSS2PRSS3 | |
| SCHEMBL13162156 | 0.82 | CA12 (0.38) | F10F7 | |
| SCHEMBL6872185 | 0.81 | F10 (0.42) | F10F7PRSS1PRSS2PRSS3 | |
| SCHEMBL7147108 | 0.81 | PDE10A (0.35) | IDO1 | |
| SCHEMBL7147090 | 0.80 | F10 (0.53) | F10F7PRSS1PRSS2PRSS3 | |
| SCHEMBL6874415 | 0.79 | F10 (0.52) | F10F7PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548694-B2 | Anticoagulants | HOFFMAN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| EP-1289939-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-12 | — | — | EP | disclosed |
| US-20020004608-A1 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | US | disclosed |
| WO-2001090051-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004608-A1 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | GLS, SLC6A5, GLRA1 | F10 546/4885F7 422/4885PRSS1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.